A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Isatuximab (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms PomdeSAR
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Dec 2017 According to a sanofi media release, updated results from this study will be presented at upcoming American Society of Hematology meeting.
    • 24 Nov 2017 Planned End Date changed from 12 Feb 2018 to 19 Aug 2020.
    • 24 Nov 2017 Planned primary completion date changed from 12 Feb 2018 to 19 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top